Recent Updates — RDY
Dr. Reddy’s Laboratories reported consolidated revenues of ₹86,708 million for the quarter ended September 30, 2026, a decline of 1.5% year-over-year but an increase of 7.4% sequentially. Profit after tax attributable to equity holders stood at ₹9,250 million (EPS: ₹11.10), down 36% from the prior year period but up 109% from the previous quarter, which was impacted by a ₹2,397 million provision for semaglutide API issues. EBITDA reached ₹17,828 million with a margin of 20.6%. For the half-year, revenues were ₹167,413 million and profit after tax was ₹13,685 million. The company operates in the global pharmaceutical industry, manufacturing generic drugs, biosimilars, active pharmaceutical ingredients, and contract development and manufacturing services.
The Board of Directors approved the appointment of Mr. Akhil Ravi as Head API and Services and Senior Management Personnel, inducting him into the Management Council effective November 13, 2026. Mr. Ravi currently serves as CEO of Aurigene Pharmaceutical Services Ltd., a wholly owned subsidiary, where he has led growth and capability expansion over nearly 19 years with the company. He is the son-in-law of Co-Chairman and Managing Director G V Prasad. Dr Reddy's Laboratories Limited operates in the pharmaceutical industry, developing and manufacturing generic medicines, active pharmaceutical ingredients (APIs), and biotechnology products.
Dr. Reddy’s Laboratories reported a net profit of Rs9.1 billion (U.S.$120 million) for the quarter ended September 30, 2026, down from Rs14.3 billion in the prior-year period. Revenue declined to Rs86.7 billion from Rs88.1 billion as cost of revenues rose to Rs41.5 billion. Operating profit fell to Rs12.7 billion from Rs17.5 billion due to higher selling, general and administrative expenses and research and development costs. The company operates in the pharmaceutical industry, developing and manufacturing generic medicines, biosimilars, and active pharmaceutical ingredients.
The Central Drugs Standard Control Organisation of India has approved Zytorvi (toripalimab) in combination with cisplatin and paclitaxel for the first-line treatment of adult patients with unresectable advanced, recurrent or metastatic esophageal squamous cell carcinoma. This marks the second approved indication for the drug in India, following its initial approval for nasopharyngeal carcinoma. The approval is based on Phase 3 JUPITER-06 trial data showing a 42% reduction in disease or death risk and median overall survival of 17.7 months compared to 12.9 months with chemotherapy alone. Dr. Reddy's Laboratories Ltd. is a global pharmaceutical company headquartered in Hyderabad, India.